[The advances of clinical and molecular prognostic factors of diffuse large B-cell lymphoma].
作者信息
Wang S N, Bai O
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):538-41. doi: 10.3760/cma.j.issn.0253-2727.2016.06.022.
Abstract
摘要
相似文献
1
[The advances of clinical and molecular prognostic factors of diffuse large B-cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):538-41. doi: 10.3760/cma.j.issn.0253-2727.2016.06.022.
2
Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Mod Pathol. 1999 May;12(5):546-52.
3
Prognostic factors in large-cell lymphoma.
Clin Adv Hematol Oncol. 2003 May;1(5):269-70.
4
Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma.
Oncotarget. 2017 Jul 18;8(29):47790-47800. doi: 10.18632/oncotarget.17830.
5
Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.
6
Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Expert Rev Hematol. 2016 May;9(5):471-7. doi: 10.1586/17474086.2016.1146584. Epub 2016 Feb 19.
7
Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma.
Br J Haematol. 2008 Apr;141(2):265-8. doi: 10.1111/j.1365-2141.2008.07028.x.
8
Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review.
Crit Rev Oncol Hematol. 2019 Jan;133:1-16. doi: 10.1016/j.critrevonc.2018.10.006. Epub 2018 Nov 1.
9
Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma.
Int J Lab Hematol. 2019 Dec;41(6):754-761. doi: 10.1111/ijlh.13106. Epub 2019 Sep 17.
10
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.
Br J Haematol. 2014 Oct;167(1):133-6. doi: 10.1111/bjh.12930. Epub 2014 May 3.
本文引用的文献
1
[Advances of aberrant signaling pathways and related targeting drugs in B cell non- Hodgkin lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2015 Dec;36(12):1049-52. doi: 10.3760/cma.j.issn.0253-2727.2015.12.015.
2
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
Blood. 2016 Feb 18;127(7):858-68. doi: 10.1182/blood-2015-05-645069. Epub 2015 Nov 24.
3
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Blood. 2016 Feb 11;127(6):739-48. doi: 10.1182/blood-2015-06-654111. Epub 2015 Nov 19.
4
Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Oncotarget. 2015 Dec 22;6(41):43881-96. doi: 10.18632/oncotarget.6316.
5
Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Oncotarget. 2015 Dec 8;6(39):42232-42. doi: 10.18632/oncotarget.6273.
6
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13.
7
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Blood. 2015 Apr 9;125(15):2336-43. doi: 10.1182/blood-2014-08-595934. Epub 2015 Feb 18.
8
High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.
Int J Hematol. 2015 Feb;101(2):140-7. doi: 10.1007/s12185-014-1719-3. Epub 2014 Dec 12.
9
Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling.
Exp Cell Res. 2015 Feb 1;331(1):58-72. doi: 10.1016/j.yexcr.2014.09.034. Epub 2014 Oct 7.
10
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Br J Haematol. 2015 Jan;168(2):239-45. doi: 10.1111/bjh.13116. Epub 2014 Sep 19.
Zotero 插件